AML market $400 million growing to $3.5 billion in 5 years., page-2

Agreed BT,

One of the things with rac's drug originally is that it was hard to make lots of money from it, as the market value was not so great. But with the fda's recent Orphan Drug Act that has completely changed. Orphan drugs are one of the biggest pharmaceutical growth areas.

And when you look at race's drug's efficacy and safety profile, you realise that they have a great drug. And it's almost completely risk free, as it's already been successful in many drug trials.

There are many companies with mkt caps over $100m that don't have proven drug efficacy, and here is rac that does and it's worth $13m!